Skip to main content
. 2021 May 24;24(6):102643. doi: 10.1016/j.isci.2021.102643

Figure 5.

Figure 5

Signaling pathway involved in FliI activation

(A) FliI activated ERK1/2 in chondrocytes stimulated with FliI (5μg/mL) as evidenced by increased expression of pERK1/2.

(B) Dose-dependent manner of FliI in activating ERK1/2 and MEK1/2.

(C) Quantification of the relative densities of the detected bands of pERK1/2 and pMEK1/2 for triplicates and significant difference was determined by the One-way ANOVA, followed by Tukey's multiple-comparison procedure.

(D) Effects of different doses of MEK1/2 inhibitor U0126 on expression of to ERK1/2, MMP13, MMP3, c-Myc and RUNX2 after FliI activation.

(E) Western blot analysis showing that deduction of ERK1/2 expression due to U0126 is associated with reduction of expression of MMP3.

(F) Quantification of the relative densities of the detected bands of pERK1/2 and MMP3 for triplicates and significant difference was determined by the One-way ANOVA, followed by Tukey's multiple-comparison procedure.

(G) Pull-down assay showing the ability of FliI to bind TLR4 of chondrocytes.

(H) Involvement of TLR4 in signaling mediated by FliI activation as analyzed by western blotting.

(I) Gene expression of MMP3 and MMP13 in FliI-stimulated chondrocytes after treatment with TAK-242. Results for triplicates and significant difference was determined by the One-way ANOVA, followed by Tukey's multiple-comparison procedure.